This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance
by Zacks Equity Research
Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
by Zacks Equity Research
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.
Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca
by Zacks Equity Research
GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.
Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed
by Kinjel Shah
GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results
AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.
Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales
by Zacks Equity Research
Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) second-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Is a Beat in Store for Gilead (GILD) in This Earnings Season?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.
CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.
Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?
by Zacks Equity Research
Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.
Pfizer (PFE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter Humira LOE.
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.
GSK Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company reports.
Astrazeneca (AZN) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $65.25, moving -0.17% from the previous trading session.
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
by Zacks Equity Research
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.
AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use
by Zacks Equity Research
AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.
UnitedHealth Group (UNH) Q2 Earnings Beat, Hikes '22 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter results gain from revenue growth stemming from solid segmental contributions and membership growth. A raised 2022 EPS view remains noteworthy.
Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate
by Zacks Equity Research
Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.
Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY
by Kinjel Shah
FDA grants priority review to Roche's (RHHBY) BLA for Lunsumio. AstraZeneca (AZN) announces a small acquisition. Pfizer (PFE) files NDA for Paxlovid.
Company News for Jul 6, 2022
by Zacks Equity Research
Companies in The News Are: F, STLA, AZN, CVX.
AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline
by Zacks Equity Research
AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $65.95 in the latest trading session, marking a -0.18% move from the prior day.